Oslo, Norway, 9 May 2018: Photocure ASA (OSE: PHO), held its annual general meeting on 9 May 2018 at 17:00 hours (CET).
All proposals were resolved as presented in the notice convening the annual general meeting dated 16 April 2018, except for item 12 regarding two weeks' notice period for extraordinary general meetings, as further set out in the minutes from the general meeting attached hereto.
For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000, Email: ed@photocure.no
About Photocure ASA
Photocure, The Bladder Cancer Company, delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
